Loading...

Child Innovac - Nasal vaccine against whooping cough

1,382 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jan 12, 2011

Despite large coverage with efficacious vaccines, whooping cough is still a major cause of global childhood morbidity and mortality. In an effort to solve this problem, the Child-Innovac programme has developed a new vaccine designed to be given as a single dose at birth in order to protect young children, under 6 months of age, which is the most vulnerable age group and not sufficiently protected by the current vaccines. The new vaccine is based on a novel concept of nasal administration of the live genetically attenuated whooping cough agent, which in pre-clinical animal tests has been shown to be perfectly safe and able to induce strong, rapid and long-lasting protection against the infection. Within the frame of the Child- Innovac project, this vaccine will now be administered for the first time to man. If successful, it will constitute a novel platform to vaccinate by nasal administration against a number of different respiratory infections and other diseases.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...